Quote:
Originally Posted by Bill Bumface
Don't kid yourself, the driver for this wasn't Denmark. It was the $8B and growing revenue they have in the US now.
First approval was in the US as well. Just because there are foreign companies that make drugs the US market and approval processes are driving the bus for global pharma.
|
Yeah, I just thought it was funnier to link it to somehow protecting the long-term interests of the Danish chocolate industry by keeping T2D at bay.
Quote:
Originally Posted by The Fisher Account
Are these drugs all injections or can you take them in pill form now?
|
Only Ozempic (semaglutide) has an oral variant -- called Rybelsus -- and there isn't technically an oral Wegovy equivalent. This may sound counterintuitive since they're literally all semaglutide under the hood, but it's the dosing regimen that makes Ozempic and Rybelsus approved for T2D, and Wegovy approved for obesity. Bioavailability of oral semaglutide is ~1%, meaning the
maximum dose of Rybelsus (14mg/day) is the equivalent of about half the maximum dosage of Ozempic (2mg/week, so 1mg). So you need a much higher dose for lesser results, and it needs to be taken daily. Or you could just do a once-a-week tiny-ass pen needle or insulin pin.
Mounjaro/Zepbound does not have an approved oral version. The oral version of Ozempic uses an absorption enhancer called SNAC (heh) which is Novo's own IP, but Mounjaro is developed by Lilly and I don't see any way Lilly pays to license the tech from Novo.